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Cytokines and inhibitors in plasma were measured in 44 patients with typhoid fever. Ex vivo
production of the cytokines was analyzed in a whole blood culture system with and without
lipopolysaccharide (LPS). Acute phase circulating concentrations of cytokines (±SD) were as
follows: interleukin (IL)-IP, <140 pg/ml.; tumor necrosis factor-a (TNFa), 130 ± 50 pg/mL;
IL-6, 96 ± 131 pg/ml.; and IL-8, 278 ± 293 pg/ml., Circulating inhibitors were elevated in the
acute phase: IL-l receptor antagonist (IL-IRA) was 2304 ± 1427 pg/ml, and soluble TNF
receptors 55 and 75 were 4973 ± 2644 pgJmL and 22,865 ± 15,143 pgJmL, respectively. LPS-
stimulated production of cytokines was lower during the acute phase than during convalescence
(mean values: IL-IP, 2547 vs. 6576 pg/ml.; TNFa, 2609 vs. 6338 pg/rnl.; IL-6, 2416 vs. 7713
pg/ml.), LPS-stimulated production orIL-iRA was higher in the acute than during the convales-
cent phase (5608 vs. 3977 pg/mL). Inhibited production of cytokines during the acute phase may
bedue to a switch from a proinflammatory to an antiinflammatory mode.
Typhoid fever is caused by the facultative intracellular
gram-negative bacillus Salmonella typhi and occasionally by
Salmonella paratyph i. Although salmonellae contain lipo-
polysaccharide (LPS; bacterial endotoxin), the clinical pic-
ture of typhoid fever differs from gram-negative sepsis, and
the role ofendotoxin in the pathophysiology oftyphoid fever
is controversial [I].
The proinflammatory cytokines interleukin (IL)-I,8, tu-
mor necrosis factor-a (TNFa; cachectin), IL-6, and IL-8
have been implicated in the pathogenesis of sepsis caused by
gram-negative microorganisms [2-4]. When LPS is injected
intravenously into animals or human volunteers, elevated
concentrations of these cytokines can be detected, and the
symptoms and signs of sepsis are mimicked [5-7]. Elevated
circulating levels of TNFa have been correlated with poor
prognosis in sepsis, meningococcemia, and cerebral malaria
[7-10]. In contrast, in infections with intracellular patho-
gens, such as Leishmania species, Listeria monocytogenes, or
mycobacteria, administration of TNFa inhibits the out-
growth of the microorganisms, whereas administration of an-
Received 13 September 1993; revised 12 January 1994.
Presented in part: Third International Workshop on Cytokines, Sienna,
Italy, 10-14 November 1991.
Patients gave informed consent, and guidelines for human experimenta-
tion of the Dr. Kariadi Hospital, Diponegoro University, were followed.
Grant support: Scientific Research in the Tropics. Netherlands Founda-
tion for Science.
Reprints or correspondence: Dr. Monique Keuter, University Hospital,
Dept. of Internal Medicine. P.O. Box 910 I, 6500 HB Nijmegen, Nether-
lands.
The Journal of Infectious Diseases 1994;169:1306-11
© 1994 by The University of Chicago. All rights reserved.
0022-1899/94/6906-0017$01.00
tibodies to this cytokine are detrimental [11-16], In experi-
mental Salmonella typhimurium infection in mice. the role
of TNFa is similar to that in other intracellular infections
[17-19). However, in calves with S. typhimurium sepsis, the
cytokine pattern appears to differ from that seen after intrave-
nously administered LPS. Where TNFa rose 1 h after LPS
administration, salmonella sepsis caused a barely detectable
increase in TN Fa [20].
In contrast to these animal studies, circulating cytokines
(TNFa, IL-6, and IL-l,8) were elevated in children with ty-
phoid fever in Chile (21). Butler et al. [22] studied the out-
come of typhoid fever in adults in Nepal and found that
higher values of IL-6 and soluble TNF receptor p55 were
related to poorer outcome.
In 1989, joint research on several aspects of typhoid fever
was started between Nijmegen University and Diponegoro
University. To obtain more insight into the pathophysiology
oftyphoid fever, we measured levels ofcirculating pyrogenic
cytokines (IL-l,8, TNFa, TNF,8 [lymphotoxin], and IL-6)
and concentrations of IL-8, the cytokine inhibitor IL-l re-
ceptor antagonist (IL-l RA), and the soluble TNF receptors
p55 and p75 (sTNF-R). In addition, we investigated the ca-
pacity of blood cells to produce IL-l,8, TNFa, IL-6, and IL-
IRA ex vivo in the acute and convalescent phases of hospital-
ized patients with typhoid fever.
We used the whole blood cytokine test as described by van
Deuren et al. [23] and Nerad et al. [24]. This assay is simple,
reproducible, and especially suitable fOT use in laboratories
that are not particularly well equipped for work with cyto-
kines. In addition, the method may be less artificial than is
isolating mononuclear cells over a gradient and probably is a
more natural mirror ofwhat happens in vivo, because plasma
factors and other cells are left in situ.
JlD 1994;1 69 (June) Cytokines in Typhoid Fever 1307
Table 1. Characteristics of 44 hospitalized culture-proven ty-
phoid fever patients.
The study was done in Dr. Kariadi Hospital, Diponegoro Uni-
versity, Sernarang, Indonesia, beginning in December 1990.
Blood and bone marrow cultures were done for all adult patients
(> 14 years old) hospitalized with suspected typhoid fever (de-
fined as fever >38.5°C and at least one of the following signs:
relative bradycardia, abdominal complaints, mental changes,
signs ofcomplicated typhoid fever, enlarged liver or spleen and
no apparent other disease). If blood or bone marrow cultures
were positive for S. typhi or S. paratyphi A or patients were
found to have perforated ilea at surgical exploration, typhoid
fever was considered proven.
A total of 44 patients were studied. Patient characteristics are
shown in table I. Complications of typhoid fever were defined
as gastrointestinal bleeding, intestinal perforation, shock, delir-
ium, stupor or coma, pneumonia, or diffuse intravascular coagu-
lation.
Treatment consisted of chloramphenicol (40 mg/kg/day
orally) if leukocyte counts were > 2 X 109/L. If fever did not
subside within 6 days, treatment was changed to sulfamethoxa-
zole (800 mg) and trimethoprim (160 mg) twice daily or ampi-
cillin (I g four times daily). Surgical patients received ampicil-
lin, metronidazole, and gentamicin during and after surgery. No
cyclooxygenase inhibitors were given. Only 2 patients received a
single dose of 120 mg of dexamethasone, but not before blood
was obtained for cytokine measurement. Most patients were dis-
charged 7-10 days after defervescence, which we defined as con-
valescence. No patients died.
Cytokine measurements. On admission and during convales-
cence, blood was drawn for cytokine measurement. Venous
blood samples were aseptically collected into sterile 4-mL tubes
(Vacutainer; Becton Dickinson, Rutherford, NJ) containing
EDTA. Unless stated otherwise, a total of 3 tubes of blood was
drawn from each patient [23). To each tube, 250 JLL ofaprotinin
(Trasylol 2500 kallikreine inactivating units [KIU]; Bayer, Le-
verkusen, Germany; final concentration 625 KIU/mL) was
added through the stopper by a tuberculin needle and syringe.
One tube was centrifuged directly (1250 g, 10 min), platelets
from the supernatant plasma were removed by a second centrifu-
Patients and Methods
Characteristic
No. of patients
Mean age(range), years
Males/females
Median (range) of
days with fever
before admission
Leukocyte countat
admission (range)
Complications
Pneumonia
Delirium
Perforation
Bleeding
Complicated disease
16
20 (14-34)
7/9
10.0 (4-20)
7.3 X 109/L(2.6-37.0)
16
10
2
5
1
Uncomplicated disease
28
24 (14-60)
12/16
8.5 (4-30)
4.4 X I09/L (1.6-7.4)
gation ( I5,000 g, I min), and plasma was collected and stored at
-20°C until assayed for cytokines. To one of the two remaining
tubes, 50 JLL of LPS (Escherichia coli serotype 055:B5; Sigma,
St. Louis; final concentration 10 JLg/mL) was added to stimulate
cytokine production. Unstimulated samples contained apro-
tinin only (no LPS). Both tubes were incubated at 37°C for 24 h.
For 17 (random) patients, a fourth 4-mL tube of blood was
obtained in the acute phase into which indomethacin was added
(0.5 JLg/mL final concentration). For 26 (random) patients, we
obtained a total of six tubes of blood. From two of these, we
removed the plasma, replacing it with a like amount of PBS.
TNFa was determined by an RIA (detection level 100 pg/
ml.), described in [25). Normal TNFa values for our laboratory
(circulating concentrations and ex vivo production without LPS
below the detection limit and ex vivo production after 24 h of
stimulation with LPS) are 3780 ± 950 pg/ml.,
IL- I,B was measured by RIA according to the method of Lisi
et al. [26] but without chloroform extraction (detection level
140 pg/mL). Normal values for our laboratory (circulating con-
centrations and ex vivo production without LPS below the de-
tection limit and ex vivo production after 24 h of stimulation
with LPS) are 6930 ± 3160 pg/ml.,
IL-6 was measured by an ELISA as described (detection level,
20 pg/ml.) [27). Normal values for our laboratory (circulating
concentrations and ex vivo production without LPS) were below
the detection limit.
IL-8 was measured by ELISA quantikine (R & D Systems,
Europe, Abingdon, UK). The detection limit was 45 pg/mL,
and normal values were below the detection limit. We sought
TNF~ (lymphotoxin) by ELISA quantikine (R & D Systems,
Europe) but failed to detect any. IL-IRA was determined by an
RIA according to the method of Poutsiaka et al. [28] (detection
level 300 pg/mL). Normal values for our laboratory (circulating
concentrations and ex vivo production without LPS below the
detection limit, ex vivo production after 24 h stimulation with
LPS) were 5757 ± 1060 pg/ml.,
sTNF-R was measured by an enzyme-linked immunobinding
assay (Hoffman-La Roche, Basel, Switzerland; detection level,
80 and 300 pg/mL for p55 and p75, respectively). Normal val-
ues for circulating concentrations are 1.50 ng/rnl, (p55) and
2.51 ng/ml, (p75). All samples from the same patient were ana-
lyzed in the same run in duplicate to minimize analytical errors.
Statistics. When frequency distribution was parametric, we
used paired and unpaired Student's t test. When not parametric,
Wilcoxon signed-rank test or Mann-Whitney U test was used. P
< .05 was considered significant.
Results
Circulating cytokines and inhibitors during acute and conva-
lescent phases oftyphoidfever. Coneen trations of pyrogenic
cytokines during the acute phase (IL-l,B, IL-6, TNFa, lym-
photoxin) are shown in figure I. IL- I,B concentrations were
below the detection limit in both acute and convalescent
phases. IL-6 concentrations ranged from undetectable «20
pg/mL) to 600 pgjmL (median, 73). TNFa concentrations
ranged from below the detection limit to 310 pgjmL (me-
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Figure 1. Circulating concentrations of pyrogenic cytokines in-
terleukin (Il,)-1{J, tumor necrosis factor (TN F)-a, Il-6, and IL-8 in
patients during acute phase of typhoid fever. Patients had been ill
> I week. Horizontal continuous circles = detection limit; horizon-
tal bars = median values. In comparison with normal values, IL-6,
Il-8, and TNFa are slightly elevated.
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dian, 110) in the acute phase and to 300 pg/ml, (median,
below detection limit) during the convalescent phase. All
lymphotoxin concentrations were below detection limits
during acute and convalescent phases. IL-8 concentrations
were detectable in the acute phase (median, 145; range, 47-
998 pg/mL) but lower during the convalescent phase (me-
dian, 46; range, 46-180 pg/mL).
Inhibitors such as IL-I RA and sTNF-R (p55 and p75)
were significantly higher in the acute phase than during the
convalescent phase: IL-IRA, 2304 ± 1427 pg/mL versus
469 ± 324 pg/ml.; sTNF-R55, 4973 ± 2644 pg/mL versus
1671 ± 532 pg/mL; and sTNF-R75, 22,865 ± 15,143 pg/
mL versus 5971 ± 2750 pg/mL (figure 2).
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Circulating cytokines and inhibitors in complicated and un-
complicated disease. No differences were found in circulat-
ing cytokines or inhibitors between the 16 patients with com-
plicated and the 28 patients with uncomplicated disease
courses.
Ex vivo production ofcytokines and inhibitors during acute
and convalescent phases. Unstimulated whole blood cul-
tures did not have detectable IL-II3, TNFa, or IL-6 (not
shown). After incubation with LPS for 24 h, the supernatants
contained detectable amounts of these cytokines, which
were significantly lower in the acute phase than in convales-
cence (IL-II3: 2547 ± 3319 vs. 6576 ± 6275 pg/ml., P <
.00 I; TNFa: 2609 ± 2443 vs. 6338 ± 4366 pg/mL, P <
.001; IL-6: 2416 ± 1531 vs. 7713 ± 3809 pg/rnl., P = .01;
figure 3).
In the acute phase, there was a correlation between the
LPS-stimulated production of IL-113 and TNFa (r = .664),
IL-l{j and IL-6 (r = .531), and TNFa and IL-6 (r = .434).
Such correlations were not found during convalescence.
When indomethacin was added to the stimulated samples,
the concentrations of TNFa and IL-I{j in the acute phase
were not different from those without indomethacin (2859 ±
2630 vs. 2609 ± 2443 and 2782 ± 2821 vs. 2547 ± 3319
pg/rnl, for TNFa and IL-II3, with and without indometha-
cin, respectively). Also, removal of plasma and replacement
with PBS did not change the stimulated production of TNFa
and IL-l {j in the acute phase (TNFa: 3307 ± 3920 pg/ml.;
u-is. 2244 ± 2512 pg/mL).
The IL-l RA concentrations found in unstimulated cul-
tures (not shown) were similar to those during the acute
phase. However, the LPS-stimulated production of IL-l RA
was high and reached significantly higher concentrations in
the acute phase of the disease (5608 ± 1832 pg/mL) than
during convalescence (3977 ± 1974 pg/mL; P < .05). sTNF-
R, IL-8, and lymphotoxin were not generated in the cultures.
Ex vivo production ofcytokines and inhibitors during com-
plicated and uncomplicated courses ofdisease. In the acute
convalescent
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Figure 2. Individual concentrations ofcirculating interleukin (Il)-l receptor antagonist (ra) and tumor necrosis factor (sTNF-R) soluble
receptors 55 and 75 in patients during acute and convalescent phases of typhoid fever. Inhibitors like Il-lra and sTNF-R (p55 and p75)
were significantly higher in acute phase than during convalescent phase.
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Figure 3. Individual production capacityof interleukin(IL)-ll3. tumor necrosisfactor(TNF)-a. and IL-6in acute and during convales-
cent phasesof typhoidfever. After incubation with lipopolysaccharide for24 h. supernatantscontained detectableamounts of cytokines,
which were significantly lowerin acute phase than duringconvalescence.
phase , patients with complicated disease had significantly
less IL-I {j production after ex vivo stimulation with LPS
(1341 ± 1373 vs, 6563 ± 1342 pg/ml.; P < .005) and a trend
towards lower TNFa production (1650 ± 1407 vs. 3064 ±
2770 pg/mL; P = .06) . Such differences were not found for
the production of IL-I RA or IL-6. During the convalescent
phase . the ex vivo-stimulated production of IL-I (j and
TNFa did not differ for complicated and uncomplicated
cases of disease.
Discussion
In this study we found several signs ofcytokine activation
during typhoid fever. The concen trations ofcirculating inhib-
itors such as IL-IRA and sTNF-R were high in the acute
phase ofthe disease. IL-I RA is known not to be detectable in
the circulation of normal subjects. Normal values for sTNF-
Rare 1.50 ng/mL (p55) and 2.5 I ng/mL (p75) [29. 30). We
also found that the production capacity of pyrogenic cyto-
kines in whole blood is depressed in the acute phase of ty-
phoid fever but is restored during the convalescent phase.
Although the patients in our study usually had severe ty-
phoid fever, we found that those with compli cated disease
courses had significantly lower proinflammatory cytokine
production capacity than did those with uncomplicated dis-
ease.
A low production capacity ofcytokines has been found in
other serious conditions. such as severe postoperative infec-
tion [31). sepsis [32-34), and attacks of familial Mediterran-
ean fever [35. 36). In these reports. all investigators used
isolated peripheral blood mononuclear cells or tissue macro-
phages. We have previously found depressed cytokine pro-
duction capacity in the whole blood culture system during
the acute phase of meningococcal disease and during Pneu-
mocystis carinii infection (unpublished data). From these
studies and the work presented here, we conclude that the
depressed cytokine production capacity is not a consequence
offewer white blood cells during the acute phase ofthe infec-
tion, since we found no correlation between leukocyte count
and cytokine production (table I).
Many investigators [31-36) have interpreted the finding of
low cytokine production capacity as exhaustion of cytokine-
producing cells, which could be a consequence of exposure
in vivo to stimuli such as endotoxin. Our finding that IL-
IRA is produced in high concentrations argues against such
a hypothesis and also rules out the possibility that the de-
creased production of proinflammatory cytokines is due to
an enhanced lysis of producing cells or to increased inactiva-
tion of LPS by lipids in the acute phase . Although we have
been unable to demonstrate that the proinflammatory cyto-
kines and IL-I RA are produced by the same kind ofcells, we
hypothesize that after the initial phase of infection. cytokine-
producing cells switch from a balanced proinflammatory to
an antiinflammatory repertoire. Our findings that patients in
the acute phase of typhoid fever have high concentration of
soluble sTNF-Rs in their blood is in agreement with this
notion.
Since our cultures used whole blood , we investigated
whether some common circulating factor could be responsi-
ble for the correlated low production capacity of the cyto-
kines IL-I{j, TNFa, and IL-6 in the acute phase. Cyclooxy-
genase products. such as prostaglandin E2• which inhibit
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production of IL-l and TNFa [37], were not responsible
since addition of indomethacin to the whole blood cultures
did not lead to significant changes in cytokine production.
Likewise, removal of plasma and addition of saline before
incubation did not overcome the suppression in the acute
phase of the disease.
It is possible that exposure in vivo to other inhibitory fac-
tors will explain the low cytokine production capacity.
Schindler et al. [38] demonstrated that exposure of isolated
mononuclear cells to IL-6 inhibits the production of IL-l
and TNFa. In the present study, we found no correlation
between IL-6 concentrations in plasma and the magnitude of
the production ofIL-l {1 and TNF (r = .041 and .035, respec-
tively). Exposure to other cytokines such as, IL-4, IL-l 0, and
transforming growth factor-S could, however, play a role.
Vannier et al. [39] have provided evidence that exposure of
cells to IL-4 suppresses the IL-l production but up-regulates
the synthesis of IL-I RA.
With few exceptions, patients with typhoid fever have a
continuous fever. Hence, pyrogenic cytokines would be ex-
pected to be present in the circulation during the acute phase
of the disease. In our series of febrile patients with typhoid
fever, we could not detect appreciable concentrations of the
pyrogenic cytokines IL-l {1, TNFa, and lymphotoxin. The
concentrations of IL-6, generally considered a relatively
weak pyrogen [40], were low compared to findings with
other febrile conditions [3, 41]. We did detect elevated con-
centrations of IL-8, but this cytokine is considered nonpyro-
genic [42].
Thus, the question of which pyrogens are responsible for
the continuous fever in typhoid fever remains unanswered.
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